Aussie anaesthetic
October 29, 2013
Melbourne-based
Drawbridge Pharmaceuticals has
announced that patents on its
lead anaesthetic drug candidate
Phaxan (alphaxalone formulated in
sulfobutyl ether beta cyclodextrin)
have been granted in Australia,
New Zealand, the UK, Hong Kong,
Singapore and South Africa.
Phaxan is a novel water-based
formulation of alphaxalone, and is
claimed to be superior to propofol
with a wide therapeutic index and
rapid onset and offset of action.
The anaesthetic agent in Phaxan
has been administered in the
past as Althesin when formulated
in a different excpient, and was
withdrawn in 1984 because of
problems with the formulation.
Phaxan doesn’t have these issues,
and the granting of the patents
will add significant value to the
Australian company.
Drawbridge chief medical officer,
Colin Goodchild, said the case for
the use of Phaxan in modern critical
care is compelling, with the need
for a new anaesthetic that is both
safe and effective continuing to
grow significantly.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Oct 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Oct 13
